Clinical trialNCT05272384RecruitingPhase 1Interventional

Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma

SponsorNational Cancer Institute (NCI)Enrollment32Recurrent B-Cell Non-Hodgkin LymphomaRecurrent Diffuse Large B-Cell LymphomaRecurrent Hodgkin LymphomaRefractory B-Cell Non-Hodgkin LymphomaRefractory Diffuse Large B-Cell LymphomaRefractory Hodgkin Lymphoma

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This phase I trial tests the safety, side effects, and best dose of nivolumab in combination with ASTX727 in treating B-cell lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. ASTX727 consists of the combination of decitabine and cedazuridine. Cedazuridine is in a class of medications called cytidine deaminase inhibitors. It prevents the breakdown of decitabine, making it more available in the body so that decitabine will have a greater effect. Decitabine is in a class of medications called hypomethylation agents. It works by helping the bone marrow produce normal blood cells and by killing abnormal cells in the bone marrow. Giving nivolumab in combination with ASTX727 may shrink and stabilize cancer.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Catherine S Diefenbach
Laura and Isaac Perlmutter Cancer Center at NYU Langone
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

9 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States
Active, not recruiting
City of Hope Comprehensive Cancer Center
Duarte, California, United States
Matthew Mei
Recruiting
University of California Davis Comprehensive Cancer Center
Sacramento, California, United States
Joseph M. Tuscano
Recruiting
Yale University
New Haven, Connecticut, United States
Tarsheen Sethi
Recruiting
University of Chicago Comprehensive Cancer Center
Chicago, Illinois, United States
Justin P. Kline
Recruiting
Uc Comprehensive Cancer Center at Silver Cross
New Lenox, Illinois, United States
Justin P. Kline
Recruiting
University of Chicago Medicine-Orland Park
Orland Park, Illinois, United States
Justin P. Kline
Recruiting
Nyu Langone Hospital - Long Island
Mineola, New York, United States
Catherine S. Diefenbach
Recruiting
Laura and Isaac Perlmutter Cancer Center at Nyu Langone
New York, New York, United States
Catherine S. Diefenbach
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Decitabine and CedazuridineNivolumab →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 3 Nov 2022
Primary completion: 28 Jun 2027
Completion: 28 Jun 2027
Last update posted: 13 May 2026
Registered enrollment: 32
Registry id: NCT05272384

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.